IP Library Granted Patent US 7,276,255
Granted Patent B2
US 7,276,255 · App. 10/830,878 · Granted Oct 2, 2007

Wound and ulcer treatment with super-oxidized water

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,276,255
App. No.
10/830,878
Granted
Oct 2, 2007
Kind
B2
Abstract

Super-oxidized water based on hypochlorous acid, such as is obtained by the electrochemical treatment of a saline solution, may be used in the treatment of leg ulcers or other open wounds. Preferably, the pH of the super-oxidized water is in a range of 4 to 7, and the water has a redox potential of >950 mV. Medicaments based on the super-oxidized water may be in liquid or gel form. The super-oxidized water is able to control the microbial population within the wound and at the same time permit cell proliferation.

Claims (36)

1. A method for treating an open wound in a human or animal body comprising administering to the open wound an output solution comprising hypochlorous acid,

said output solution: having a pH of 4 to 7, a redox potential of >950 mV, and being obtained by electrochemical treatment of a saline solution; and

wherein the output solution is administered in an amount effective to act as a biocide and permit cell proliferation for wound healing.

2. The method according to claim 1 , wherein the open wound is an ulcer, burn, or surface wound.

3. The method according to claim 1 , wherein the output solution is in a liquid form and is applied to the wound by bathing.

4. The method according to claim 3 , wherein the output solution is applied to the wound by immersion in a hydrobath containing the output solution.

5. The method according to claim 1 , wherein the output solution is in a liquid form and is applied to the wound by spraying.

6. The method according to claim 1 , wherein the output solution is in a gel form and is topically applied to the wound.

7. The method according to claim 1 , wherein the output solution has a pH of 4.0 to 6.5.

8. The method according to claim 7 , wherein the output solution has a pH of 4.0 to 6.2.

9. The method according to claim 8 , wherein the output solution has a pH of 4.3 to 6.2.

10. The method according to claim 9 , wherein the output solution has a pH of about 5.4.

11. The method according to claim 1 , wherein the output solution has a redox potential of about 1000 mV.

12. The method according to claim 1 , wherein the output solution, or a preparation derived therefrom, has a biocide rate (D Value) of approximately 1 log reduction unit bacillus subtilis spores in less than 1 minute with a 9:1 output solution: innoculum mix.

13. The method according to claim 1 , wherein the output solution is diluted.

14. The method according to claim 13 , wherein the output solution is diluted to an extent that it promotes cell proliferation.

15. The method according to claim 1 , wherein the output solution has a pH adjusted to a desired level by using an alkaline solution output from an electrochemical cell in which the saline solution is treated.

16. The method according to claim 1 , wherein the output solution further comprises a phosphate buffer to adjust a pH of the solution to a desired level.

17. The method according to claim 1 , wherein the output solution has an available free chlorine concentration of about 144 mg/l to 400 mg/l.

18. A method for treating an open wound in a mammal comprising administering to the open wound an output solution obtained by electrochemical treatment of a saline solution, the output solution comprising hypochlorous acid, having an available free chlorine concentration of about 144 mg/l to 400 mg/l, and having a pH of 4 to 7, wherein the output solution is administered in an amount effective to act as a biocide and permit cell proliferation for wound healing.

19. The method according to claim 18 , wherein the open wound is an ulcer, burn, or surface wound.

20. The method according to claim 18 , wherein the output solution is in a liquid form and is applied to the wound by bathing.

21. The method according to claim 18 , wherein the output solution is applied to the wound by immersion in a hydrobath containing the output solution.

22. The method according to claim 18 , wherein the output solution is in a liquid form and is applied to the wound by spraying.

23. The method according to claim 18 , wherein the output solution is in a gel form and is topically applied to the wound.

24. The method according to claim 18 , wherein the output solution has a pH of 4.0 to 6.5.

25. The method according to claim 18 , wherein the output solution has a pH of 4.0 to 6.2.

26. The method according to claim 18 , wherein the output solution has a pH of 4.3 to 6.2.

27. The method according to claim 18 , wherein the output solution has a pH of about 5.4.

28. The method according to claim 18 , wherein the output solution has a redox potential of >950 mV.

29. The method according to claim 18 , wherein the output solution has a redox potential of about 1000 mV.

30. The method according to claim 18 , wherein the output solution, or a preparation derived therefrom, has a biocide rate (D Value) of approximately 1 log reduction unit bacillus subtilis spores in less than 1 minute with a 9:1 output solution: innoculum mix.

31. The method according to claim 18 , wherein the output solution is diluted.

32. The method according to claim 18 , wherein the output solution is diluted to an extent that it promotes cell proliferation.

33. The method according to claim 18 , wherein the output solution has a pH adjusted to a desired level by using an alkaline solution output from an electrochemical cell in which the saline solution is treated.

34. The method according to claim 18 , wherein the output solution further comprises a phosphate buffer to adjust a pH of the solution to a desired level.

Assignments (9)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 7, 2019
From: REALM THERAPEUTICS, INC.
To: URGO US, INC.
Reel/Frame 049405/0191 →
CHANGE OF NAME Recorded Jan 5, 2017
From: PURICORE, INC.
To: REALM THERAPEUTICS, INC.
Reel/Frame 041268/0225 →
RELEASE OF SECURITY INTEREST Recorded Mar 17, 2016
From: PACIFIC WESTERN BANK (AS SUCCESSOR IN INTEREST BY MERGER TO SQUARE 1 BANK)
To: PURICORE, INC.
Reel/Frame 038019/0196 →
SECURITY AGREEMENT Recorded Jan 27, 2014
From: PURICORE, INC.
To: SQUARE 1 BANK
Reel/Frame 032126/0844 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 14, 2011
From: PURICORE INTERNATIONAL LIMITED
To: PURICORE, INC.
Reel/Frame 025644/0164 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 11, 2007
From: PURICORE EUROPE LIMITED
To: PURICORE INTERNATIONAL LIMITED
Reel/Frame 019406/0928 →
CHANGE OF NAME Recorded Jun 8, 2007
From: STERILOX MEDICAL (EUROPE) LIMITED
To: PURICORE EUROPE LIMITED
Reel/Frame 019398/0820 →
RE-RECORD TO CORRECT THE NAME AND ADDRESS OF THE ASSIGNEE, PREVIOUSLY RECORDED ON REEL 017821 FRAME 0907. Recorded May 31, 2007
From: SELKON, JOHN B.
To: STERILOX MEDICAL (EUROPE) LIMITED
Reel/Frame 019372/0207 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 26, 2006
From: SELKON, JOHN B.
To: STERILOX TECHNOLOGIES INTERNATIONAL LIMITED
Reel/Frame 017821/0907 →